Mallinckrodt public limited company (MNK)
(Delayed Data from NYSE)
$16.14 USD
+0.44 (2.80%)
Updated May 3, 2019 04:02 PM ET
After-Market: $16.14 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.14 USD
+0.44 (2.80%)
Updated May 3, 2019 04:02 PM ET
After-Market: $16.14 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured highlights include: Mallinckrodt, Dell, American Axle, Daqo and General Motors
by Zacks Equity Research
Zacks.com featured highlights include: Mallinckrodt, Dell, American Axle, Daqo and General Motors
6 Low Price-to-Book Stocks for Value Investors
by Zacks Equity Research
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
by Zacks Equity Research
Continued price erosion and intensifying competition in generic drug market is negatively impacting the top line of industry participants. However, stabilizing outlook is encouraging.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports fourth-quarter results.
Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
6 Low Price-to-Book Value Stocks to Buy in February
by Zacks Equity Research
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again
by Zacks Equity Research
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3
by Zacks Equity Research
Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.
Mylan's Generic Version of Advair Diskus Wins FDA Approval
by Zacks Equity Research
Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Dell Technologies, American Axle & Manufacturing, Magna International and General Motors
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Dell Technologies, American Axle & Manufacturing, Magna International and General Motors
6 Promising Price-to-Book Value Stocks With Solid Prospects
by Zacks Equity Research
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
by Zacks Equity Research
Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.
Cara (CARA) Up on IDMC's Recommendation to Continue Trial
by Zacks Equity Research
Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.
Heron Gains on Priority Review Designation for Pain Drug
by Zacks Equity Research
Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.
Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
by Zacks Equity Research
Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).
Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA
by Zacks Equity Research
Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.
Mallinckrodt (MNK) to Separate Generics & Branded Businesses
by Zacks Equity Research
Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.